Q-omics provides the consensus-scored CD40LG profile across patient tissues and cancer cell-line models. CD40LG expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CD40LG is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CD40LG RNA expression shows 21,474 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where CD40LG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD40LG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD40LG survival associations across molecular data types. CD40LG RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD40LG RNA expression–survival associations across cancer types. High CD40LG expression shows unfavorable associations in LGG, but favorable associations in HNSC, LUAD, UCEC, OV and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CD40LG RNA expression.
This table summarizes CD40LG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CD40LG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD40LG shows lower tumor expression in COAD, HNSC, LUSC, THCA and BLCA and higher tumor expression in KIRC. The KIRC box plot shows higher CD40LG RNA expression in tumor versus normal tissue (log2 FC = +1.139, t-test p < 0.001).
This table shows molecular features associated with CD40LG in patient tissues and cancer cell lines. In patient samples, CD40LG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD40LG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
